IONS
Ionis Pharmaceuticals, Inc.
September 15, 2026 · market open
- Rarity
- 1.84
- Peak move
- −9.04%
- Float cap
- $8.2B
Ionis Pharmaceuticals is a commercial-stage biotechnology company that discovers and develops RNA-targeted medicines for serious diseases. It markets seven therapies, including treatments for familial chylomicronemia syndrome, hereditary angioedema, hereditary transthyretin-mediated amyloidosis, spinal muscular atrophy, SOD1-ALS, and related rare disorders. Its medicines are sold to patients in the U.S., Europe, and other regions directly and through partners such as AstraZeneca, Biogen, and Sobi.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
3 events · 0 from SEC or newswire · 0 timed with the moveanalyst_ratingGuggenheim cut its price target on Ionis Pharmaceuticals to $80 from $89 while keeping a Buy rating, citing a poll of 30 U.S. cardiologists and lipidologists projecting about 40% year-end 2027 adoption of Tryngolza in severe hypertriglyceridemia versus management guidance of more than $3 billion in peak sales.
analyst_ratingGuggenheim cut its price target on Ionis Pharmaceuticals to $80 from $89 while maintaining a Buy rating, after a survey of 30 US cardiologists and lipidologists projected ~40% adoption of Tryngolza in severe hypertriglyceridemia by end-2027; the firm models ~$2.9B peak Tryngolza sales versus management guidance of more than $3B and ~$160M peak Zanvastro sales, and removed pelacarsen from its model after the Lp(a)-HORIZON failure.
clinical_readoutIonis partner Novartis reported that the Phase 3 Lp(a)HORIZON trial of pelacarsen in 8,323 patients with elevated Lp(a) and established cardiovascular disease failed to meet its primary endpoint, lowering Lp(a) but not reducing cardiovascular events versus placebo.